Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Hematology

Infectious Diseases

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.7502